EASL Studio - S3E16 - Liver cancer in 2022: Wrap-up & outlook
1 بازدیدها
administrator
07/13/23
Results from current clinical trials are rapidly evolving, with mixed results. In this EASL Studio the faculty discuss:
why certain trials have failed whereas others have succeeded,
what we have learned about the connection between overall survival and progression-free survival as endpoints, and
how the systemic therapy of HCC has evolved.
بیشتر نشان بده، اطلاعات بیشتر
نظرات فیس بوک
نظری یافت نشد